Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CAD | P27708 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122645 | 1.00 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL4727586 | 1.00 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL929076 | 0.93 | KDM4E (0.52) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Pyruvate SCHEMBL6571338 | 0.93 | MAPT (0.56) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Pyruvate SCHEMBL6573546 | 0.93 | MAPT (0.56) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL930333 | 0.93 | KDM4E (0.52) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Cysteamine SCHEMBL20768365 | 0.91 | ALOX15 (0.50) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL9292612 | 0.86 | KDM4E (0.44) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL9292614 | 0.86 | KDM4E (0.44) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL4990411 | 0.86 | CAD (0.44) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626414-A1 | SYNERGISTIC COMBINATIONS OF REGULATED NECROSIS INHIBITORS WITH N-ACETYLCYSTEINE | Seabelife (FR) | 2025-10-08 | — | — | EP | claimed |
| WO-2024115793-A1 | SYNERGISTIC COMBINATIONS OF REGULATED NECROSIS INHIBITORS WITH N-ACETYLCYSTEINE | SEABELIFE (FR) | 2024-06-06 | — | — | WO | claimed |
| US-20220409526-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | RETINA FOUND OF THE SOUTHWEST (US) | 2022-12-29 | — | — | US | claimed |
| US-20160008320-A1 | STATINS IN THE TREATMENT OF MUSCULAR DYSTROPHIES AND MYOPATHIES | UNIVERSITY OF WASHINGTON | 2016-01-14 | — | — | US | claimed |
| US-8575382-B2 | Low molecular weight pharmacological activity modulators | “Ivy Pharm” LLC (RU) | 2013-11-05 | — | — | US | claimed |
| CN-102802605-A | Stable lipid formulations of apoptosis promoters | ABBOTT LAB | 2012-11-28 | — | — | CN | claimed |
| US-20120202764-A1 | LOW MOLECULAR WEIGHT PHARMACOLOGICAL ACTIVITY MODULATORS | "IVY PHARM" JSC. (RU) | 2012-08-09 | — | — | US | claimed |
| EP-2455386-A1 | LOW MOLECULAR WEIGHT PHARMACOLOGICAL ACTIVITY MODULATORS | "Ivy Pharm" Jsc. (RU) | 2012-05-23 | — | — | EP | claimed |
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| EP-1231886-A4 | TOPICAL SKIN COMPOSITION | ACCESS BUSINESS GROUP INT LLC (US) | 2005-10-12 | — | — | EP | claimed |
| CN-1424900-A | Topical skin composition | TONDAR COMMERCIAL GROUP INTERN (US) | 2003-06-18 | — | — | CN | claimed |
| US-20030095959-A1 | Topical skin composition | ACCESS BUSINESS GROUP INTERNATIONAL LLC. | 2003-05-22 | — | — | US | claimed |
| EP-1231886-A1 | TOPICAL SKIN COMPOSITION | Alticor Inc. (US) | 2002-08-21 | — | — | EP | claimed |
| WO-2001037788-A1 | TOPICAL SKIN COMPOSITION | ALTICOR INC. (US) | 2001-05-31 | — | — | WO | claimed |
| EP-0300100-A1 | Method and compounds for reducing dermal inflammations | Morgan, Lee Roy (US) | 1989-01-25 | — | — | EP | claimed |
| EP-4731739-A1 | NEW COMPOUNDS | Givaudan SA (CH) | 2026-04-29 | — | — | EP | disclosed |
| EP-0300100-A1 | Method and compounds for reducing dermal inflammations | Morgan, Lee Roy (US) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202764-A1 | LOW MOLECULAR WEIGHT PHARMACOLOGICAL ACTIVITY MODULATORS | OPRM1, SIGMAR1, TACR1 | MAPT 3722/4885KDM4E 4082/4885THRB 810/4885 |
| US-20030095959-A1 | Topical skin composition | CUTA, S100A4, KRT18 | MAPT 1787/4885KDM4E 4634/4885THRB 3415/4885 |
| US-20220409526-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | PDE6C, STRA6, PDE6A | MAPT 2605/4885KDM4E 3217/4885THRB 753/4885 |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | MAPT 3440/4885KDM4E 3045/4885THRB 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.